Compare KFY & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KFY | RCUS |
|---|---|---|
| Founded | 1969 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.8B |
| IPO Year | 1998 | 2018 |
| Metric | KFY | RCUS |
|---|---|---|
| Price | $63.35 | $22.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $78.00 | $30.30 |
| AVG Volume (30 Days) | 489.5K | ★ 1.1M |
| Earning Date | 03-11-2026 | 05-28-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 42.41 | N/A |
| EPS | ★ 2.61 | N/A |
| Revenue | ★ $1,819,519,000.00 | $247,000,000.00 |
| Revenue This Year | $5.75 | N/A |
| Revenue Next Year | $4.02 | $19.94 |
| P/E Ratio | $24.01 | ★ N/A |
| Revenue Growth | ★ 12.20 | N/A |
| 52 Week Low | $58.95 | $6.79 |
| 52 Week High | $78.50 | $26.40 |
| Indicator | KFY | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 48.11 | 57.16 |
| Support Level | $62.46 | $20.35 |
| Resistance Level | $63.51 | $24.16 |
| Average True Range (ATR) | 1.77 | 1.38 |
| MACD | 0.23 | 0.44 |
| Stochastic Oscillator | 93.64 | 65.46 |
Korn Ferry is a consulting firm that powers performance. The Company helps unlock the potential in people and unleash transformation across organizations synchronizing, operations, and talent to accelerate performance, fuel growth, and inspire a legacy of change. The company's segment includes Consulting, Digital, Executive Search North America, Executive Search EMEA, Executive Search APAC, Executive Search Latin America, Professional Search & Interim and RPO. The company generates the majority of its revenue from the Executive Search segment and Consulting segment. The Executive search segment helps organizations recruit board-level, chief executive, and other C-suite/senior executive and general management talent to deliver lasting impact.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.